{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-067644","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.537467+00:00","generated_at":"2026-06-01T06:50:49.880421+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"IDEAYA darovasertib Phase 2 uveal melanoma data: 75% eye saved, 47% median tumor shrinkage","bullets":["Investigator-sponsored Phase 2: 75% of enucleation patients (9/12) had eye saved (converted to brachytherapy/EBRT) after 6 months.","Median tumor shrinkage 47% (max volume change) in 12 enucleation patients; 67% had >30% shrinkage after 6 months.","Company-sponsored Phase 2: 8 patients at ≥4 months showed median tumor volume shrinkage 72%; majority of enucleation patients converted to eye saved.","Drug-related AEs predominantly Grade 1-2; no drug-related serious AEs in either trial.","Data presented at ASCO 2024; trial enrolled over 40 patients across 14+ sites globally."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-067644","json":"https://secwatch.observer/filing/0000950170-24-067644.json","markdown":"https://secwatch.observer/filing/0000950170-24-067644.md","text":"https://secwatch.observer/filing/0000950170-24-067644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000095017024067644/0000950170-24-067644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000095017024067644/idya-20240603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:50:49.880421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}